Skip to main content
SpringerLink
Log in

Glatiramer acefante: promise in relapsing-remitting multiple sclerosis?

  • New Drugs and Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lublin FD, Reingold SC, National Multiple Sclerosis Society (USA) Advisory Committee on Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis. Results of an international survey. Neurology 1996; 46: 907–11

    Article  PubMed  CAS  Google Scholar 

  2. Lea AP, Goa KL. Copolymer-1: a review of its pharmacological properties and therapeutic potential in multiple sclerosis. Clin Immunother 1996 Oct; 6(4): 319–31

    Article  Google Scholar 

  3. Johnson KP, U.S. Phase III Copolymer 1 Study Group. Antibodies to copolymer-1 do not interfere with its clinical effect [abstract]. Ann Neurol 1995 Dec; 38: 973

    Google Scholar 

  4. Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987 Aug 13; 317: 408–14

    Article  PubMed  CAS  Google Scholar 

  5. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995 Jul; 45: 1268–76

    Article  PubMed  CAS  Google Scholar 

  6. Mancardi GL, Sardanelli F, Parodi RC, et al. The activity of copolymer-1 on gadolinium enhanced MRI lesions in relapsing remitting multiple sclerosis [abstract no. P277]. J Neurology 1996; 243(6) Suppl. 2: S13

    Google Scholar 

  7. Bornstein MB, Miller A, Slagle S, et al. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 1991 Apr; 41: 533–9

    Article  PubMed  CAS  Google Scholar 

  8. Fricker J. Developing drugs for multiple sclerosis. Lancet 1996 Oct; 348: 1022

    Article  Google Scholar 

  9. Langtry HD, Lamb HM. Cladribine: a review of its use in multiple sclerosis. BioDrugs 1998 May; 9(5): 419–33

    Article  PubMed  CAS  Google Scholar 

  10. Faulds D, Benfield P. Interferon beta-1b in multiple sclerosis: an initial review of its rationale for use and therapeutic potential. Clin Immunother 1994 Jan; 1(1): 79–87

    Article  Google Scholar 

  11. Holliday SM, Benfield P. Interferon-β-1a: a review of its pharmacological properties and therapeutic potential in multiple sclerosis. BioDrugs 1997 Oct; 8(4): 317–30

    Article  PubMed  CAS  Google Scholar 

  12. British National Formulary No. 34. London: The Pharmaceutical Press, 1997 Sept

  13. Milo R, Panitch H. Additive effects of copolymer-1 and interferon β-1b on the immune response to myelin basic protein. J Neuroimmunol 1995; 61: 185–93

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Glatiramer acefante: promise in relapsing-remitting multiple sclerosis?. Drugs Ther. Perspect 11, 1–5 (1998). https://doi.org/10.2165/00042310-199811100-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199811100-00001

Keywords

Search

Navigation